CLINICAL TRIALS PROFILE FOR ASTEPRO
✉ Email this page to a colleague
All Clinical Trials for ASTEPRO
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00720382 ↗ | A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis | Completed | Meda Pharmaceuticals | Phase 3 | 2007-03-01 | The purpose of this study is to determine if one allergy treatment (0.15% azelastine hydrochloride) is as safe as mometasone furoate (nasonex) alone. |
| NCT00783432 ↗ | Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis | Completed | Meda Pharmaceuticals | Phase 3 | 2006-07-01 | The purpose of this study is to determine if Astepro Nasal Spray (0.1% azelastine hydrochloride) is as safe as Astelin Nasal Spray (0.1% azelastine hydrochloride) |
| NCT01368445 ↗ | A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies | Completed | Meda Pharmaceuticals | Phase 3 | 2006-08-01 | The Purpose of this study is to evaluate the safety and efficacy of MP03-36 (0.15% azelastine hydrochloride)at dosages of 2 sprays per nostril once daily and 2 sprays per nostril twice daily in patients with seasonal allergic rhinitis. |
| NCT01880840 ↗ | Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR | Completed | Novella Clinical | Phase 4 | 2013-06-01 | The purpose of this study is to compare the safety of 2 different doses of the investigational use of an allergy medication (Astepro Nasal Spray) in the treatment of allergic rhinitis (AR). This is an open-label study; that is, parent and child will know which group each is in. |
| NCT01880840 ↗ | Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR | Completed | Meda Pharmaceuticals | Phase 4 | 2013-06-01 | The purpose of this study is to compare the safety of 2 different doses of the investigational use of an allergy medication (Astepro Nasal Spray) in the treatment of allergic rhinitis (AR). This is an open-label study; that is, parent and child will know which group each is in. |
| NCT06008860 ↗ | A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection | Recruiting | University of Chicago | Phase 4 | 2023-07-01 | The study team proposes to evaluate the efficacy of Astepro® 0.15% nasal spray in treating SARS-CoV-2 infection in adults through a pilot and feasibility clinical trial at the University of Chicago. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ASTEPRO
Condition Name
Clinical Trial Locations for ASTEPRO
Trials by Country
Clinical Trial Progress for ASTEPRO
Clinical Trial Phase
Clinical Trial Sponsors for ASTEPRO
Sponsor Name
